Moira Marizzoni

Dr. Moira Marizzoni

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Ageing Research Reviews
Verified
Journal Article
Closed access
LPLorenzo Pini
Lorenzo Pini
MPMichela Pievani
Michela Pievani
MBMartina Bocchetta
Martina Bocchetta
DADaniele Altomare
Daniele Altomare
PBPaolo Bosco
Paolo Bosco
GFGiovanni B. Frisoni
Giovanni B. Frisoni

1 December 2013 in NeuroImage
Verified
Journal Article
Closed access
JJJorge Jovicich
Jorge Jovicich
MMMoira Marizzoni
Moira Marizzoni
RSRoser Sala-Llonch
Roser Sala-Llonch
BBBeatriz Bosch
Beatriz Bosch
DBDavid Bartrés-Faz
David Bartrés-Faz
GFGiovanni B. Frisoni
Giovanni B. Frisoni

31 May 2023 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
MMMoira Marizzoni
Moira Marizzoni
PMPeppino Mirabelli
Peppino Mirabelli
EMElisa Mombelli
Elisa Mombelli
LCLuigi Coppola
Luigi Coppola
CFCristina Festari
Cristina Festari
GFGiovanni B. Frisoni
Giovanni B. Frisoni
Background: Increasing evidence links the gut microbiota (GM) to Alzheimer’s disease (AD) but the mechanisms through which gut bacteria influence the brain are still unclear. This study tests the hypothesis that GM and mediators of the microbiota-gut-brain axis (MGBA) are associated with the amyloid cascade in sporadic AD. Methods: We included 34 patients with cognitive impairment due to AD (CI-AD), 37 patients with cognitive impairment not due to AD (CI-NAD), and 13 cognitively unimpaired persons (CU). We studied the following systems: (1) fecal GM, with 16S rRNA sequencing; (2) a panel of putative MGBA mediators in the blood including immune and endothelial markers as bacterial products (i.e., lipopolysaccharide, LPS), cell adhesion molecules (CAMs) indicative of endothelial dysfunction (VCAM-1, PECAM-1), vascular changes (P-, E-Selectin), and upregulated after infections (NCAM, ICAM-1), as well as pro- (IL1β, IL6, TNFα, IL18) and anti- (IL10) inflammatory cytokines; (3) the amyloid cascade with amyloid PET, plasma phosphorylated tau (pTau-181, for tau pathology), neurofilament light chain (NfL, for neurodegeneration), and global cognition measured using MMSE and ADAScog. We performed 3-group comparisons of markers in the 3 systems and calculated correlation matrices for the pooled group of CI-AD and CU as well as CI-NAD and CU. Patterns of associations based on Spearman’s rho were used to validate the study hypothesis. Results: CI-AD were characterized by (1) higher abundance of Clostridia_UCG-014 and decreased abundance of Moryella and Blautia (p < .04); (2) elevated levels of LPS (p < .03), upregulation of CAMs, Il1β, IL6, and TNFα, and downregulation of IL10 (p < .05); (3) increased brain amyloid, plasma pTau-181, and NfL (p < 0.004) compared with the other groups. CI-NAD showed (1) higher abundance of [Eubacterium] coprostanoligenes group and Collinsella and decreased abundance of Lachnospiraceae_ND3007_group, [Ruminococcus]_gnavus_group and Oscillibacter (p < .03); (2) upregulation of PECAM-1 and TNFα (p < .03); (4) increased plasma levels of NfL (p < .02) compared with CU. Different GM genera were associated with immune and endothelial markers in both CI-NAD and CI-AD but these mediators were widely related to amyloid cascade markers only in CI-AD. Conclusions: Specific bacterial genera are associated with immune and endothelial MGBA mediators, and these are associated with amyloid cascade markers in sporadic AD. The physiological mechanisms linking the GM to the amyloid cascade should be further investigated to elucidate their potential therapeutic implications.

1 October 2019 in Neurobiology of Aging
Verified
Journal Article
Closed access
AAAbulaish Ansari
Abulaish Ansari
EMElisabetta Maffioletti
Elisabetta Maffioletti
EMElena Milanesi
Elena Milanesi
MMMoira Marizzoni
Moira Marizzoni
GFGiovanni B. Frisoni
Giovanni B. Frisoni
LBLuisella Bocchio-Chiavetto
Luisella Bocchio-Chiavetto

1 January 2016 in NeuroImage
Verified
Journal Article
Closed access
JJJorge Jovicich
Jorge Jovicich
LMLudovico Minati
Ludovico Minati
MMMoira Marizzoni
Moira Marizzoni
RMRocco Marchitelli
Rocco Marchitelli
RSRoser Sala-Llonch
Roser Sala-Llonch
GFGiovanni B. Frisoni
Giovanni B. Frisoni

13 August 2016 in Human Brain Mapping
Verified
Journal Article
Open access
PDF file
AAAngela Albi
Angela Albi
OPOfer Pasternak
Ofer Pasternak
LMLudovico Minati
Ludovico Minati
MMMoira Marizzoni
Moira Marizzoni
DBDavid Bartrés‐Faz
David Bartrés‐Faz
JJJorge Jovicich
Jorge Jovicich
Free water elimination (FWE) in brain diffusion MRI has been shown to improve tissue specificity in human white matter characterization both in health and in disease. Relative to the classical diffusion tensor imaging (DTI) model, FWE is also expected to increase sensitivity to microstructural changes in longitudinal studies. However, it is not clear if these two models differ in their test–retest reproducibility. This study compares a bi‐tensor model for FWE with DTI by extending a previous longitudinal‐reproducibility 3T multisite study (10 sites, 7 different scanner models) of 50 healthy elderly participants (55–80 years old) scanned in two sessions at least 1 week apart. We computed the reproducibility of commonly used DTI metrics (FA: fractional anisotropy, MD: mean diffusivity, RD: radial diffusivity, and AXD: axial diffusivity), derived either using a DTI model or a FWE model. The DTI metrics were evaluated over 48 white‐matter regions of the JHU‐ICBM‐DTI‐81 white‐matter labels atlas, and reproducibility errors were assessed. We found that relative to the DTI model, FWE significantly reduced reproducibility errors in most areas tested. In particular, for the FA and MD metrics, there was an average reduction of approximately 1% in the reproducibility error. The reproducibility scores did not significantly differ across sites. This study shows that FWE improves sensitivity and is thus promising for clinical applications, with the potential to identify more subtle changes. The increased reproducibility allows for smaller sample size or shorter trials in studies evaluating biomarkers of disease progression or treatment effects.Hum Brain Mapp 38:12–26, 2017. ©2016 Wiley Periodicals, Inc.